AASLD 2020: Odevixabat Improves Key Parameters of Pediatric Progressive Familial Intrahepatic Cholestasis
The bile acid transporter inhibitor was evaluated as long-term therapy.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.